



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/532,708	03/22/2000	Sarita Kumari Jain	A-67933-1/RFT/RMS/DAV	8874

7590

06/10/2002

Flehr Hohbach Test Albritton & Herbert LLP  
Four Embarcadero Center  
Suite 3400  
San Francisco, CA 94111-4187

EXAMINER

STRZELECKA, TERESA E

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 06/10/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Applicati n N .

09/532,708

Applicant(s)

JAIN ET AL.

Examiner

Teresa E Strzelecka

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 10 April 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 12-24,28,33 and 49-51 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 12-24,28,33 and 49-51 is/are rejected.
- 7) ☒ Claim(s) 12 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                             | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)         | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____                                    |

## **DETAILED ACTION**

### ***Continued Prosecution Application***

1. The request filed on February 22, 2002 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/532,708 is acceptable and a CPA has been established. An action on the CPA follows.
2. Amendment filed on April 10, 2002 cancelled claims 1-11, 25-27, 29-32 and 34-48. Claims 12-24, 28, 33, 48-51 are pending in the application.

### ***Claim Objections***

3. Claim 12 is objected to because of the following informalities: "nucleics acid" in line 10. Appropriate correction is required.

### ***Claim Rejections - 35 USC § 112***

4. MPEP § 2185 states:

If a "means or step plus function" limitation recited in a claim is not supported by corresponding structure, material or acts in the specification disclosure, the following rejections should be considered:

(A) under 35 U.S.C. 112, first paragraph, as not being supported by an enabling disclosure because the person skilled in the art would not know how to make and use the invention without a description of elements to perform the function. The description of an apparatus with block diagrams describing the function, but not the structure, of the apparatus is not fatal under the enablement requirement of 35 U.S.C. 112, first paragraph, as long as the structure is conventional and can be determined without an undue amount of experimentation. *In re Ghiron*, 442 F.2d 985, 991, 169 USPQ 723, 727 (CCPA 1971);

(B) under 35 U.S.C. 112, second paragraph, as being indefinite. *In re Dossel*, 115 F.3d 942, 946, 42 USPQ2d 1881, 1884 (Fed. Cir. 1997); and

(C) under 35 U.S.C. 102 or 103 where the prior art anticipates or renders obvious the claimed subject matter including the means or step that performs the function specified in the claim, the theory being that since there is no corresponding structure, etc., in the specification to limit the means or step plus function limitation, an equivalent is any element that performs the specified function.

Art Unit: 1637

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 20, 22 and 33 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 20 is drawn to a method of high throughput genomics in which at least one of the steps of making a library of variants of target nucleic acid, introducing the library into a cellular library and performing phenotypic screening of the cellular library is performed using a robotic system. Claim 22 is drawn to a method of high throughput genomics in which at least one of the steps of making a library of cells comprising mutant target nucleic acid, adding a library of candidate agents to cellular library and determining the effect of the candidate agent on the cells is performed using a robotic system. Claim 33 is drawn to a robotic system comprising a computer workstation with a microprocessor programmed to manipulate a device selected from the group consisting of a thermocycler, a multichannel pipettor, a sample handler, a plate handler, a gel loading system, a gene sequencer, an automated transformation system, a colony picker, a bead picker, a cell sorter, an incubator, a light microscope, a fluorescence microscope, a spectrofluorimeter, a spectrophotometer, a luminometer, a CCD camera and combinations thereof.

The specification does not provide a description of how to accomplish phenotypic screening of all possible phenotypic changes in cells or organisms using a robotic system, and which parts of the system would be necessary to accomplish this task. The specification does not provide a description of how to determine effects of all possible candidate agents on cells or organisms

Art Unit: 1637

containing mutated target nucleic acid with the aid of a robotic system, and which parts of the system would be necessary to accomplish this task.

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 12-24, 28, 33 and 49-51 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claim 12 is indefinite because of the limitation "... polynucleotide comprises a portion substantially complementary to a fragment of target nucleic acid and is substantially complementary to said second targeting polynucleotide...". It is unclear what degree of sequence complementarity is considered "substantial".

B) Claim 20 is indefinite because the limitation of identifying cell(s) or organism(s) with an altered phenotype using a robotic system is not supported by a description of how such identification is accomplished, especially taking into account the fact that a very large number of possible phenotypic changes have been described in the specification.

C) Claim 22 is indefinite because the limitation of identifying a candidate agent which modulates the activity of the mutant target nucleic acid using a robotic system is not supported by a description of how such process is achieved using a robotic system, especially in view of the fact that the claim encompasses all possible candidate agents.

D) Claim 33 is indefinite because it does not clearly set forth the metes and bounds of the patent protection desired, being drawn to a robotic system comprising a large number of components and combinations thereof.

Art Unit: 1637

E) Claim 49 is indefinite because of the limitation "...genomic library comprises a combination of multiple organisms...". Genomic libraries usually contain DNA.

F) Claims 50 and 51 are dependent on the cancelled claim 1.

***Claim Rejections - 35 USC § 103***

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. Claims 12-18, 28, 33 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sena et al. (U.S. Patent No. 5,273,881) and Cathcart et al. (WO 91/16675).

A) Claim 12 is drawn to a method of high throughput genomics comprising providing a plurality of enhanced homologous recombination (EHR) compositions, each comprising a recombinase, a separation moiety and a first and second targeting polynucleotide, where the first polynucleotide comprises a portion substantially complementary to a fragment of target nucleic acid and is substantially complementary to the second targeting polynucleotide, contacting the EHR compositions with a library of target nucleic acids and isolating and cloning target nucleic acids, wherein the isolating and cloning are performed using a robotic system.

Claim 13 is drawn to the target nucleic acid being a target gene, claim 14 is drawn to a fragment of the target gene, claim 15 is drawn to the target nucleic acid being a regulatory sequence. Claim 16 is drawn to the target nucleic acid comprising single nucleotide polymorphisms, claim 17 is drawn to the library of target nucleic acids comprising all or part of a cDNA library, genomic DNA library, genomic DNA samples, or combinations

thereof. Claim 18 is drawn to the genomic DNA samples being from one or more organisms. Claim 28 is drawn to sequencing the target nucleic acid. Claim 49 is drawn to the genomic library comprising a combination of multiple organisms.

Claim 33 is drawn to a robotic system comprising a computer workstation with a microprocessor programmed to manipulate a device selected from the group consisting of a thermocycler, a multichannel pipettor, a sample handler, a plate handler, a gel loading system, a gene sequencer, an automated transformation system, a colony picker, a bead picker, a cell sorter, an incubator, a light microscope, a fluorescence microscope, a spectrofluorimeter, a spectrophotometer, a luminometer, a CCD camera and combinations thereof.

B) The following descriptions were provided in the specification:

- i) means for producing a plurality of enhanced homologous recombination (EHR) compositions and means for contacting the EHR compositions with a cellular library: robotic system with a thermocycler, cooling position, automated pipettor, positions for tubes and plates (page 34, lines 11-39, page 35, line 1-29).
- ii) means for isolating target nucleic acids: robotic system with an automated pipettor, positions for tubes and plates (page 35, lines 24-39); lines 31-39 describe manual isolation of DNA.
- iii) means for producing a library of mutant nucleic acids: the process, described on page 43, lines 1-14, involves making a plurality of EHRs using a pool of targeting polynucleotides, each of which contains one or more mismatches. There is no description of how this is accomplished by a robotic system, and means for EHR formation using a robotic system were described on pages 34-35 (see above).

iv) means for sequencing target nucleic acids: not described in the specification.

Assuming standard dideoxynucleotide sequencing, a robotic system with a thermocycler, cooling position, automated pipettor, positions for tubes and plates would be sufficient.

C) Sena et al. teaches a method of detecting DNA target by:

1. providing a composition comprising a recombinase, a set of two DNA probes (polynucleotides) that each have sequences complementary to the target DNA and also contain a region of complementary overlap to each other, where the probes can be labeled for capture with biotin or digoxigenin (separation moiety),
2. contacting the composition with target DNA under conditions which permit hybridization of probes to target DNA,
3. detecting the complex containing the target DNA (col. 3, lines 40-63, col. 4, lines 31-33;).

The probe-target complex can be isolated by capturing the labeled probe on solid support (col. 4, lines 24-27) and can be used for isolation and enrichment of target DNA sequences (col. 23, lines 22-40). Target nucleic acids include DNA from a variety of organisms, and the detection can be for diagnostic purposes, such as diagnosis of infectious diseases, screening cells for the presence of other organisms, detection of gene mutations, deletions, insertions, or rearrangements (col. 13, lines 63-67; col. 14, lines 1-27). This method can also be used for mapping genes or regulatory sequences in a chromosome (col. 20, lines 42-53).

B) Sena et al. do not teach performing the providing and contacting steps using a robotic system.



Art Unit: 1637

C) Cathcart et al. teach a robotic system for performing molecular biology procedures comprising a liquid-handling instrument with a modular stations to support liquid containers, automated pipettor, heating and cooling stations, thermocycler and a magnetic separation station for performing DNA isolation, all controlled by a computer system (Abstract; page 6, third paragraph; page 7; page 8, paragraphs 1 and 2; Fig. 1; page 10-15; page 23, paragraphs 3, 4; page 24; page 25, paragraphs 1 and 2).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the robotic system of Cathcart et al. in a method of Sena et al. with a reasonable expectation of success. The motivation to do so would have been that robotic system simultaneously processed a large number of samples.

11. Claims 19 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sena et al. and Cathcart et al. as applied to claims 1 and 12 above, and further in view of Short (U.S. Patent No. 6,057,103).

A) Claims 19-20 are drawn to making a library of target nucleic acids, introducing it into a cellular library and performing phenotypic screening of the cellular library, wherein at least one of the steps uses a robotic system.

B) Neither Sena et al. nor Cathcart et al. teach making and screening libraries of nucleic acids.

C) Short teaches generation of expression libraries from isolated nucleic acids and screening such libraries by transferring the clones into cells and screening the cells (Abstract, col. 5, lines 26-35, lines 60-67). Gene libraries are generated by insertion of isolated DNA into a vector or plasmid (col. 9, lines 54-61). The library of clones is prepared by transforming suitable hosts with the vectors, and the resultant library is screened. Clones can be subjected

Art Unit: 1637

to mutagenesis to generate variants (col. 19, lines 1-16). Screening can be performed on a mixture of clones (col. 14, lines 20-40).

The cells can then be exposed to potential drug candidates in drug discovery assays (col. 18, lines 40-49).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the methods of making and screening of clone libraries and cells taught by Short in the combined method of Sena et al. and Cathcart et al.. The motivation to do so, expressly provided by Short, would have been that there was a need for bioactive compounds with novel activities.

12. Claims 21-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Skena et al. and Cathcart et al. as applied to claim 12 above, and further in view of Ghai et al. (U.S. Patent No. 5,955,269).

A) Claims 21-24 are drawn to making cells comprising target nucleic acid, adding a library of agents to cells and determining the effect of these agents on cells using a robotic system for one of the steps, where the target nucleic acid is a gene sequence knock-out or knock-in, or comprises insertion, substitution or deletion.

B) Neither Skena et al. nor Cathcart et al. teach introducing target nucleic acid into cells and screening cells against candidate agents.

C) Ghai et al. teach methods of screening for the presence of bioactive substances in food by testing for their ability to modify gene expression in cells in vitro (col. 2, lines 51-67) or in animal models (col. 3, lines 1-15). The assays measure expression of genes (col. 3, lines 66-67; col. 4, lines 1-12) or determine phenotypic changes in cells (col. 4, lines 33-39). Once

the effects of the active compound have been determined, the compound can be isolated and purified (col. 4, lines 44-50).

Genes screened in the assay include disease-associated genes or unknown genes (col. 4, lines 58-67). The target genes or gene regulatory sequences can be obtained by standard molecular biology methods from procaryotic or eucaryotic cells, cloned into a vector, and introduced into cells, which are then used for screening. Test cells are screened for changes in gene expression associated with the bioactive compound (col. 12, lines 1-15).

The expression vectors introduced into cells may contain selectable marker genes (col. 14, lines 40-50). The effects of bioactive compounds can be tested in animals, including transgenic animals (col. 16, lines 7-10; lines 44-51). The cells can be cultured and assayed using a robotic device (col. 17, lines 18-30).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the methods of Ghai et al. in a combined method of Sena et al. and Cathcart et al.. The motivation to do so, expressly provided by Ghai et al., would have been that a robotic system facilitated high throughput screening.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E Strzelecka whose telephone number is (703) 306-5877. The examiner can normally be reached on M-F (8:30-5:30).


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-3014 for After Final communications.

Art Unit: 1637

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

TS  
June 3, 2002

TJ

  
KENNETH R. HORLICK, PH.D  
PRIMARY EXAMINER

6/4/02